SEC Form SC 13G/A filed by Chinook Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Chinook Therapeutics Inc. (Amendment)

Recent Analyst Ratings for $KDNY

$KDNY Market Insights

$KDNY Insider Trading

$KDNY SEC Filings

$KDNY Analyst Ratings

$KDNY Financials

$KDNY Large Ownership Changes

$KDNY Leadership Updates

$KDNY Press Releases

Recent Analyst Ratings for
$KDNY

$KDNY
Market Insights

$KDNY
Insider Trading

$KDNY
SEC Filings

$KDNY
Analyst Ratings

$KDNY
Financials

$KDNY
Large Ownership Changes

$KDNY
Leadership Updates

$KDNY
Press Releases

Chat with this insight

Live Market Insights

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023

Wedbush Downgrades Chinook Therapeutics to Neutral, Announces $42 Price Target

Benzinga's Top Ratings Upgrades, Downgrades For August 1, 2023

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Thomas Dolca returned 13,300 shares to the company, closing all direct ownership in the company

SEC Form 4 filed by Oxtoby Andrew

SEC Form 4: Krishnan Mahesh returned 1,275 shares to the company, closing all direct ownership in the company

SEC Form 15-12G filed by Chinook Therapeutics Inc.

SEC Form EFFECT filed by Chinook Therapeutics Inc.

SEC Form S-8 POS filed by Chinook Therapeutics Inc.

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Live finance-specific insights

This live feed shows all institutional transactions in real time.

Chinook Therapeutics downgraded by Wedbush with a new price target

Piper Sandler initiated coverage on Chinook Therapeutics with a new price target

Guggenheim initiated coverage on Chinook Therapeutics with a new price target

Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress

Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congress

Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and CHK-336 Preclinical Efficacy Data at the American Society of Nephrology (ASN) Kidney Week 2022

SEC Form SC 13D/A filed by Chinook Therapeutics Inc. (Amendment)

SEC Form SC 13D filed by Chinook Therapeutics Inc.

SEC Form SC 13G/A filed by Chinook Therapeutics Inc. (Amendment)

Live Leadership Updates

Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates

Chinook Therapeutics Announces the Appointment of Robert W. Azelby to its Board of Directors

Chinook Therapeutics Announces the Appointment of Andrew Oxtoby as Chief Commercial Officer

Fastest customizable press release news feed in the world

Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

Lifshitz Law PLLC Announces Investigations of BG, KDNY, QUOT, and DICE

Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

2/14/23 12:05:52 PM ET

$KDNY

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $KDNY alert in real time by email

SC 13G/A 1 d431875dsc13ga.htm SC 13G/A SC 13G/A

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Chinook Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

16961L 106

(CUSIP Number)

December 31, 2022

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 16961L 106

(1)

Consists of 3,128,211 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P.

(2)	Based on 63,940,620 shares of Common Stock outstanding on November 4, 2022 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2022.

CUSIP No. 16961L 106

(1)

(2)	Based on 63,940,620 shares of Common Stock outstanding on November 4, 2022 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2022.

CUSIP No. 16961L 106

(1)

(2)	Based on 63,940,620 shares of Common Stock outstanding on November 4, 2022 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2022.

CUSIP No. 16961L 106

(1)

Consists of 924,299 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

(2)	Based on 63,940,620 shares of Common Stock outstanding on November 4, 2022 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2022.

CUSIP No. 16961L 106

(1)

(2)	Based on 63,940,620 shares of Common Stock outstanding on November 4, 2022 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2022.

CUSIP No. 16961L 106

(1)

(2)	Based on 63,940,620 shares of Common Stock outstanding on November 4, 2022 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2022.

CUSIP No. 16961L 106

(1)

Consists of (i) 3,128,211 shares of Common Stock held directly by Frazier Life Sciences Public Fund, L.P. and (ii) 924,299 shares of Common Stock held directly by Frazier Life Sciences X, L.P. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences Public Fund, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick J. Heron and James N. Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the shares held by Frazier Life Sciences X, L.P.

(2)	Based on 63,940,620 shares of Common Stock outstanding on November 4, 2022 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2022.

CUSIP No. 16961L 106

(1)

(2)	Based on 63,940,620 shares of Common Stock outstanding on November 4, 2022 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2022.

CUSIP No. 16961L 106

(1)

(2)	Based on 63,940,620 shares of Common Stock outstanding on November 4, 2022 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2022.

CUSIP No. 16961L 106

(1)

(2)	Based on 63,940,620 shares of Common Stock outstanding on November 4, 2022 as set forth in the Issuer’s Quarterly Report on Form 10-Q as filed with the SEC on November 10, 2022.


Item 1(a).		Name of Issuer: Chinook Therapeutics, Inc.

Item 1(b).		Address of Issuer’s Principal Executive Offices: 400 Fairview Avenue North, Suite 900, Seattle, Washington 98102

Item 2(a).		Name of Person Filing: The entities and persons filing this statement (collectively, the “Reporting Persons”) are: Frazier Life Sciences Public Fund, L.P. (“FLSPF”) FHMLSP, L.P. FHMLSP, L.L.C. Frazier Life Sciences X, L.P. (“FLS X”) FHMLS X, L.P. FHMLS X, L.L.C. James N. Topper (“Topper”) Patrick J. Heron (“Heron”) Albert Cha (“Cha”) James Brush (“Brush” and together with Topper, Heron and Cha, the “Members”)

Item 2(b).		Address of Principal Business Office or, if none, Residence: The address and principal business office of the Reporting Persons is: c/o Frazier Life Sciences Management, L.P. 70 Willow Road, Suite 200 Menlo Park, CA 94025

Item 2(c).		Citizenship:


Entities:	FLSPF	–	Delaware, U.S.A.
	FHMLSP, L.P.	–	Delaware, U.S.A.
	FHMLSP, L.L.C.	–	Delaware, U.S.A.
	FLS X	–	Delaware, U.S.A.
	FHMLS X, L.P.	–	Delaware, U.S.A.
	FHMLS X, L.L.C.	–	Delaware, U.S.A.

Individuals:	Topper	–	United States Citizen
	Heron	–	United States Citizen
	Cha	–	United States Citizen
	Brush	–	United States Citizen


Item 2(d).		Title of Class of Securities: Common Stock

Item 2(e).		CUSIP Number: 16961L 106

Item 3.		If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:


(a)	☐	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

(b)	☐	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)	☐	Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);

(d)	☐	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)	☐	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)	☐	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)	☐	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)	☐	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


(i)	☐	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)	☐	A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

(k)	☐	Group, in accordance with §240.13d–1(b)(1)(ii)(K).

	If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution: ____

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

(a)

Amount Beneficially Owned: See Row 9 of cover page for each Reporting Person.

(b)

Percent of Class: See Row 11 of cover page for each Reporting Person

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.

(ii)

Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.

(iii)

Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.

(iv)

Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

Item 5.

Ownership of 5 Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

Item 6.

Ownership of More than 5 Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group

Each member of the group is identified on the signature page to this Schedule 13G amendment.

Item 9.

Notice of Dissolution of a Group

Not applicable.

Item 10.

Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Date: February 14, 2023	FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.

	By: FHMLSP, L.P., its General Partner
	By: FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: February 14, 2023	FHMLSP, L.P.

	By: FHMLSP, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: February 14, 2023	FHMLSP, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: February 14, 2023	FRAZIER LIFE SCIENCES X, L.P.

	By: FHMLS X, L.P., its General Partner
	By: FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: February 14, 2023	FHMLS X, L.P.
	By: FHMLS X, L.L.C., its General Partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: February 14, 2023	FHMLS X, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: February 14, 2023	By:	*
		James N. Topper

Date: February 14, 2023	By:	*
		Patrick J. Heron

Date: February 14, 2023	By:	**
		Albert Cha

Date: February 14, 2023	By:	**
		James Brush


Date: February 14, 2023	By:	/s/ Steve R. Bailey
		Steve R. Bailey, as Attorney-in-Fact

*	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on March 29, 2016.

**	This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.

Get the next $KDNY alert in real time by email

Date	Price Target	Rating	Analyst
8/8/2023	$42.00	Outperform → Neutral	Wedbush
3/6/2023	$41.00	Overweight	Piper Sandler
3/1/2023	$43.00	Buy	Guggenheim
12/5/2022	$30.00	Overweight	Wells Fargo
6/28/2022	$30.00	Buy	Stifel

Names of Reporting Persons

Frazier Life Sciences Public Fund, L.P.

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐ (b) ☒

SEC USE ONLY

Citizenship or Place of Organization

Delaware